The putative benefits of Mediterranean, DASH, MIND, Nordic, and Okinawan-style patterns are unlikely to be explained solely by nutrient density
Key Leaders: Steve Hoerter, Chief Executive Officer
This triple-agonist mechanism targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, creating synergistic effects that outperform conventional single-target medications
Our team of licensed healthcare providers, nurse practitioners, and compassionate health coaches collaborates to provide comprehensive guidance
B.JanmohamedS.D'AgostinoR
At the 12mg dose in TRIUMPH-1: Average weight loss of 28.3% at 80 weeks within the range of bariatric surgery outcomes 45.3% of participants lost 30% or more the threshold associated with bariatric surgery in published literature 65.3% achieved BMI below 30 no longer classifiable as obese by standard criteria Extension data to 104 weeks shows 30.3% average continuing to approach surgical outcomes with longer treatment The comparison is not a simple equivalence